Pancoast tumor other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
{{CMG}}{{AE}}{{Mazia}}
{{CMG}}{{AE}}{{Mazia}}
==Overveiw==
==Overveiw==
Other diagnostic studies for evaluating the spread of Pancoast tumor include bone scintigraphy, [[PET scan]], molecular tests and biopsy.
Other [[diagnostic]] studies for evaluating the spread of Pancoast tumor include [[pulmonary angiography]], molecular tests and [[biopsy]].


==Other Diagnostic Studies==
==Other Diagnostic Studies==
Other diagnostic studies for evaluating the spread of Pancoast tumor include pulmonary angiography, molecular tests and biopsy.
Other [[diagnostic]] studies for evaluating the spread of Pancoast tumor include [[pulmonary angiography]], molecular tests and [[biopsy]].
===Pulmonary Angiography===
===Pulmonary Angiography===
*On pulmonary angiography, findings of Pancoast tumor may be used for:<ref name="pmid5483666">{{cite journal |vauthors=Delarue NC, Sanders DE, Silverberg SA |title=Complementary value of pulmonary angiography and mediastinoscopy in individualizing treatment for patients with lung cancer |journal=Cancer |volume=26 |issue=6 |pages=1370–8 |year=1970 |pmid=5483666 |doi= |url=}}</ref>
*On [[pulmonary angiography]], findings of Pancoast tumor may be used for:<ref name="pmid5483666">{{cite journal |vauthors=Delarue NC, Sanders DE, Silverberg SA |title=Complementary value of pulmonary angiography and mediastinoscopy in individualizing treatment for patients with lung cancer |journal=Cancer |volume=26 |issue=6 |pages=1370–8 |year=1970 |pmid=5483666 |doi= |url=}}</ref>
:*Evaluation of central pulmonary artery invasion
:*Evaluation of central [[pulmonary artery]] [[invasion]]


===Molecular Test===
===Molecular Test===
Molecular tests include epidermal growth factor receptor ([[EGFR]]) mutation and [[anaplastic lymphoma kinase]] (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present.
Molecular tests include [[epidermal growth factor receptor]] ([[EGFR]]) [[Mutations|mutation]] and [[anaplastic lymphoma kinase]] (ALK) [[mutation]]. Specific targeted agents may be administered to [[patients]] if these [[mutations]] are present. A [[Transthoracic needle aspiration|transthoracic needle biopsy]] and a [[bronchoscopy]] are conducted to [[diagnose]] [[lung cancer]].
A transthoracic needle biopsy and a bronchoscopy are conducted to diagnose lung cancer.


===Biopsy===
===Biopsy===
A transthoracic needle biopsy, guided by CT or [[fluoroscopy]], is for pancoast tumors located in the periphery of the lungs since peripheral tumors are not accessible through a bronchoscope.<ref name="pmid24484269">{{cite journal |vauthors=Kinsey CM, Arenberg DA |title=Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging |journal=Am. J. Respir. Crit. Care Med. |volume=189 |issue=6 |pages=640–9 |year=2014 |pmid=24484269 |doi=10.1164/rccm.201311-2007CI |url=}}<nowiki><ref name="pmid12820712"></nowiki>{{cite journal |vauthors=Yung RC |title=Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy |journal=Respir Care Clin N Am |volume=9 |issue=1 |pages=51–76 |year=2003 |pmid=12820712 |doi= |url=}}</ref><ref name="NSCLS2">Squamous cell carcinoma of the lung. Libre Pathology http://librepathology.org/wiki/Squamous_cell_carcinoma_of_the_lung Accessed on March 1, 2016</ref>
A [[Transthoracic needle aspiration|transthoracic needle biopsy]], guided by [[CT-scans|CT]] or [[fluoroscopy]], is for pancoast tumors located in the [[periphery]] of the [[lungs]] since [[Periphery|peripheral]] [[tumors]] are not accessible through a [[bronchoscope]].<ref name="pmid24484269">{{cite journal |vauthors=Kinsey CM, Arenberg DA |title=Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging |journal=Am. J. Respir. Crit. Care Med. |volume=189 |issue=6 |pages=640–9 |year=2014 |pmid=24484269 |doi=10.1164/rccm.201311-2007CI |url=}}<nowiki><ref name="pmid12820712"></nowiki>{{cite journal |vauthors=Yung RC |title=Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy |journal=Respir Care Clin N Am |volume=9 |issue=1 |pages=51–76 |year=2003 |pmid=12820712 |doi= |url=}}</ref><ref name="NSCLS2">Squamous cell carcinoma of the lung. Libre Pathology http://librepathology.org/wiki/Squamous_cell_carcinoma_of_the_lung Accessed on March 1, 2016</ref>


*Other diagnostic modalities for pancoast tumor include :<ref name="pmid24484269">{{cite journal |vauthors=Kinsey CM, Arenberg DA |title=Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging |journal=Am. J. Respir. Crit. Care Med. |volume=189 |issue=6 |pages=640–9 |year=2014 |pmid=24484269 |doi=10.1164/rccm.201311-2007CI |url=}}</ref>
*Other [[diagnostic]] modalities for pancoast tumor include :<ref name="pmid24484269">{{cite journal |vauthors=Kinsey CM, Arenberg DA |title=Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging |journal=Am. J. Respir. Crit. Care Med. |volume=189 |issue=6 |pages=640–9 |year=2014 |pmid=24484269 |doi=10.1164/rccm.201311-2007CI |url=}}</ref>
:*Thoracotomy
:*[[Thoracotomy]]
:*Thoracoscopy
:*[[Thoracoscopy]]
:*Mediastinoscopy
:*[[Mediastinoscopy]]
::*Chamberlain procedure  
::*[[Chamberlain procedure]]
::*Left parasternal mediastinotomy  
::*Left parasternal mediastinotomy  
::*Anterior mediastinotomy  
::*[[Anterior]] mediastinotomy  
:*Transthoracic percutaneous [[fine needle aspiration]]
:*[[Transthoracic needle aspiration|Transthoracic]] [[percutaneous]] [[fine needle aspiration]]
:*Sputum cytology   
:*[[Sputum]] [[cytology]]  
::*The sensitivity or sputum cytology varies by location of the lung cancer
::*The [[sensitivity]] or [[sputum]] [[cytology]] varies by location of the [[lung cancer]]
*The majority of these procedures allow staging of mediastinal lymph nodes.  
*The majority of these procedures allow [[Cancer staging|staging]] of [[mediastinal]] [[lymph nodes]].  
*The table below summarizes the different types of diagnostic modalities for Pancoast tumor arranged from the most to the least invasive.<ref name="staging">Lung Cancer Staging. Wikipedia.https://en.wikipedia.org/wiki/Lung_cancer_staging Accessed on March 1, 2015 </ref>
*The table below summarizes the different types of diagnostic modalities for Pancoast tumor arranged from the most to the least [[invasive]].<ref name="staging">Lung Cancer Staging. Wikipedia.https://en.wikipedia.org/wiki/Lung_cancer_staging Accessed on March 1, 2015 </ref>


{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
Line 41: Line 40:
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Thoracotomy]]  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Thoracotomy]]  
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Allows the most thorough inspection and sampling of lymph node stations
*Allows the most thorough [[Inspection (medicine)|inspection]] and [[sampling]] of [[Lymph nodes|lymph node]] stations
*May be followed by resection of tumor, if feasible
*May be followed by resection of [[tumor]], if feasible
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Invasive approach
*[[Invasive]] approach
*Not indicated for staging alone
*Not indicated for [[Staging (pathology)|staging]] alone
*Significant risk of procedure-related morbidity
*Significant risk of procedure-related [[morbidity]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | Left parasternal mediastinotomy  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | Left parasternal mediastinotomy  
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Allows evaluation of the aortopulmonary window lymph nodes
*Allows evaluation of the [[aortopulmonary window]] [[lymph nodes]]
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*More invasive
*More [[invasive]]
*False-negative rate approximately 10%
*[[False-negative]] rate approximately 10%
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | Chamberlain procedure  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Chamberlain procedure]]
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Access to station 5 ([[aortopulmonary window]] lymph node)
*Access to station 5 ([[aortopulmonary window]] lymph node)
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Limited applications, invasive
*Limited applications, [[invasive]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Mediastinoscopy|Cervical mediastinoscopy]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Mediastinoscopy|Cervical mediastinoscopy]]
Line 66: Line 65:
*Excellent for 2RL 4RL
*Excellent for 2RL 4RL
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Invasive
*[[Invasive]]
*Does not cover all mediastinal lymph node stations; particularly subcarinal lymph nodes (station 7), paraesophageal and pulmonary ligament lymph nodes (stations 8 and 9).
*Does not cover all [[mediastinal]] [[Lymph nodes|lymph node]] stations; particularly subcarinal [[lymph nodes]] (station 7), paraesophageal and [[pulmonary]] ligament [[lymph nodes]] (stations 8 and 9).
*False-negative rate approximately 20%
*[[False-negative]] rate approximately 20%
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Thoracoscopy|Video-assisted thoracoscopy]]
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Thoracoscopy|Video-assisted thoracoscopy]]
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Useful for the evaluation of inferior mediastinum, station 5 and 6 lymph nodes
*Useful for the evaluation of [[inferior mediastinum]], station 5 and 6 [[lymph nodes]]
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Invasive
*[[Invasive]]
*Does not cover superior anterior mediastinum
*Does not cover superior [[anterior mediastinum]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | Transthoracic percutaneous [[fine needle aspiration]] under CT guidance
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | Transthoracic percutaneous [[fine needle aspiration]] under CT guidance
Line 81: Line 80:
*Widely available than some other methods
*Widely available than some other methods
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Traverses a lot of lung tissue
*Traverses a lot of [[lung]] [[tissue]]
*High pneumothorax risk
*High [[pneumothorax]] risk
*Some lymph node stations inaccessible
*Some [[lymph node]] stations inaccessible
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Bronchoscopy]] with blind transbronchial Wang needle
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Bronchoscopy]] with blind transbronchial Wang needle
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Less invasive than above methods
*Less [[invasive]] than above methods
| style="padding: 5px 5px; background: #F5F5F5;" |  
| style="padding: 5px 5px; background: #F5F5F5;" |  
*Relatively low yield
*Relatively low yield
*Not widely practiced
*Not widely practiced
*Bleeding risk
*[[Bleeding]] risk
|-
|-
|}
|}

Revision as of 17:34, 4 March 2018


Pancoast tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancoast tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancoast tumor other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancoast tumor other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancoast tumor other diagnostic studies

CDC onPancoast tumor other diagnostic studies

Pancoast tumor other diagnostic studies in the news

Blogs on Pancoast tumor other diagnostic studies

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Pancoast tumor other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overveiw

Other diagnostic studies for evaluating the spread of Pancoast tumor include pulmonary angiography, molecular tests and biopsy.

Other Diagnostic Studies

Other diagnostic studies for evaluating the spread of Pancoast tumor include pulmonary angiography, molecular tests and biopsy.

Pulmonary Angiography

Molecular Test

Molecular tests include epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) mutation. Specific targeted agents may be administered to patients if these mutations are present. A transthoracic needle biopsy and a bronchoscopy are conducted to diagnose lung cancer.

Biopsy

A transthoracic needle biopsy, guided by CT or fluoroscopy, is for pancoast tumors located in the periphery of the lungs since peripheral tumors are not accessible through a bronchoscope.[2][3]

  • The majority of these procedures allow staging of mediastinal lymph nodes.
  • The table below summarizes the different types of diagnostic modalities for Pancoast tumor arranged from the most to the least invasive.[4]
Procedure Advantages Disadvantages
Thoracotomy
Left parasternal mediastinotomy
Chamberlain procedure
Cervical mediastinoscopy
  • Considered the gold standard (usual comparitor)
  • Excellent for 2RL 4RL
Video-assisted thoracoscopy
Transthoracic percutaneous fine needle aspiration under CT guidance
  • Widely available than some other methods
Bronchoscopy with blind transbronchial Wang needle
  • Relatively low yield
  • Not widely practiced
  • Bleeding risk

References

  1. Delarue NC, Sanders DE, Silverberg SA (1970). "Complementary value of pulmonary angiography and mediastinoscopy in individualizing treatment for patients with lung cancer". Cancer. 26 (6): 1370–8. PMID 5483666.
  2. 2.0 2.1 Kinsey CM, Arenberg DA (2014). "Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging". Am. J. Respir. Crit. Care Med. 189 (6): 640–9. doi:10.1164/rccm.201311-2007CI. PMID 24484269.<ref name="pmid12820712">Yung RC (2003). "Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy". Respir Care Clin N Am. 9 (1): 51–76. PMID 12820712.
  3. Squamous cell carcinoma of the lung. Libre Pathology http://librepathology.org/wiki/Squamous_cell_carcinoma_of_the_lung Accessed on March 1, 2016
  4. Lung Cancer Staging. Wikipedia.https://en.wikipedia.org/wiki/Lung_cancer_staging Accessed on March 1, 2015

Template:WH Template:WS